English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To investigate potential cost savings associated with the use of real‐time continuous glucose monitoring ( RT ‐ CGM ) throughout pregnancy in women with Type 1 diabetes.    Methods  A budget impact model was developed to estimate, from the perspective of National Health Service England, the total costs of managing pregnancy and delivery in women with Type 1 diabetes using self‐monitoring of blood glucose ( SMBG ) with and without  RT ‐ CGM . It was assumed that the entire modelled cohort ( n  = 1441) would use  RT ‐ CGM  from 10 to 38 weeks’ gestation (7 months). Data on pregnancy and neonatal complication rates and related costs were derived from published literature, national tariffs, and device manufacturers.    Results  The cost of glucose monitoring was £588 with  SMBG  alone and £1820 with  RT ‐ CGM . The total annual costs of managing pregnancy and delivery in women with Type 1 diabetes were £23 725 648 with  SMBG  alone, and £14 165 187 with  SMBG  and  RT ‐ CGM ; indicating potential cost savings of approximately £9 560 461 from using  RT ‐ CGM . The principal drivers of cost savings were the daily cost of neonatal intensive care unit ( NICU ) admissions (£3743) and the shorter duration of  NICU  stay (mean 6.6 vs. 9.1 days respectively). Sensitivity analyses showed that  RT ‐ CGM  remained cost saving, albeit to lesser extents, across a range of  NICU  costs and durations of hospital stay, and with varying numbers of daily  SMBG  measurements.    Conclusions  Routine use of  RT ‐ CGM  by pregnant women with Type 1 diabetes, would result in substantial cost savings, mainly through reductions in  NICU  admissions and shorter duration of  NICU  care.

Modelling potential cost savings from use of real‐time continuous glucose monitoring in pregnant women with Type 1 diabetes